JPMorgan resumes Kimberly Clark stock coverage with neutral rating
JPMorgan resumed coverage of Kimberly-Clark (KMB) with a Neutral rating and a $113 price target. The stock trades at $111.34, with InvestingPro suggesting it is undervalued. JPMorgan projects 2027 and 2028 EPS of $7.03 and $8.10, respectively. KMB reported Q3 2026 earnings of $1.70 per share on $4.13B revenue, beating estimates. The company completed its Kenvue acquisition and maintained its 2026 outlook despite challenges.
How this was made
The 30-second read
Why it matters
For traders, the main decision input is the new $113 target and the model assumptions (EPS path and P/E multiple) tied to integration risk, with supporting context from the Q3 beat and maintained 2026 outlook.
Market read
A resumed analyst coverage note with a specific target and valuation framework, plus reminders of Q3 beat and integration progress, may influence near-term positioning but is not a fresh fundamental shock.
What to watch
Integration execution risk is emphasized via the valuation multiple, but the piece does not quantify synergy delivery timing or downside scenarios beyond qualitative integration-risk language.
Background
JPMorgan previously restricted coverage, then resumed with a Neutral rating after Kimberly Clark’s Q3 2026 results and the Kenvue transaction close on Nov. 2.
Ticker impact
JPMorgan resumed coverage on Kimberly Clark with a Neutral rating and set a $113 price target after updating its model post Q3 results and the Kenvue close.
Likely mild downside or range-bound trading as the stock sits just below the newly set $113 target, while investors weigh integration risk versus dividend support.
The piece is primarily an analyst-coverage restart with a specific target and model assumptions, not a new operational surprise. It does include Q3 beat and acquisition completion context, but those are presented as background rather than clearly first-disclosed facts in this article.
Market effects
Adds incremental sentiment to US consumer staples, but does not introduce a sector-wide catalyst beyond one firm’s integration-risk framing.
Limited, as the story is US-listed and focused on company-specific integration and valuation.
Low, despite mention of Chinese market challenges, because the actionable item is an analyst target update.
Counterpoint
The article’s own details (Q3 beat, raised dividend streak, productivity gains) could support a more constructive view than the Neutral rating implies.
Key entities
- companyKimberly Clark
US consumer staples company covered by JPMorgan; subject of the resumed coverage and target update.
- financial_institutionJPMorgan
Analyst firm resuming coverage with a Neutral rating and $113 price target.
- companyKenvue
Transaction referenced as closed Nov. 2, with integration underway under a new operating model.





